Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune escape. Here, we studied neutralizing antibodies and T cell responses targeting SARS-CoV-2 D614G [wild type (WT)] and the Beta, Delta, and Omicron variants of concern in a cohort of 60 health care workers after immunization with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273, or BNT162b2. High binding antibody levels against WT SARS-CoV-2 spike (S) were detected 28 days after vaccination with both mRNA vaccines (mRNA-1273 or BNT162b2), which substantially decreased after 6 months. In contrast, antibody levels were lower after Ad26.COV2.S vaccination…

• H
  Health~Holland

  Award: EMCLHS20017
• EC
  European Commission

  Award: 101003589
• Z
  ZonMw

  Awards: 10430072110001, 10150062010008
• NI
  National Institutes of Health

  Award: 101003589
• NI
  National Institute of Allergy and Infectious Diseases

  Award: 101003589